Grace Therapeutics, Inc. Common Stock
GRCEGrace Therapeutics, Inc. (GRCE) is a biopharmaceutical company focused on developing innovative therapies for the treatment of neurological and neurological-related disorders. The company engages in the identification, development, and commercialization of novel medications designed to address unmet medical needs in various medical conditions.
$3.19 0.00 (0.00%)
Company News
Grace Therapeutics Announces Results From Pivotal Phase 3 STRIVE-ON Safety Trial of GTx-104 in aSAH
Grace Therapeutics announced that its Phase 3 STRIVE-ON trial for GTx-104, a novel injectable formulation of nimodipine, met its primary endpoint and showed evidence of clinical benefit over oral nimodipine in aSAH patients. The company plans to submit a New Drug Application (NDA) for GTx-104 in the first half of 2025.
